BioSyent Inc.

Q2/H1 2026 Results

AUGUST 20, 2026

PRESENTED BY: RENÉ GOEHRUM
PRESIDENT AND CEO

DISCLAIMER

This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for BioSyent Inc., business and operational results.

By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to obtain governmental regulatory approvals, product recalls, competition from similar products and other factors including those risks and uncertainties identified above.

BioSyent Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.

BioSyent

BioSyent

We bring proven healthcare products to patients and their providers.

WHAT

Specialty Pharmaceuticals

Oral Health Products

WHERE

FeraMAX Therapeutic Thérapeutique 150

Thyconvi

RepaGyn

PerioMonitor™

Florida Probe VoiceWorks

X-PUR

Cathejell®

FeraMAX Powder Poudre 15

Papacárie Duo

inofolic

GENGIGEL®
0.2% HYALURONIC ACID TOPICAL GEL

FeraMAX Maintenance Entretien 45

Cetacaine®

WOODPECKER®

Tibella®
Tibelia Global

Advantage Arrest™

Proktis-M®

Protect-It®
The Natural Choice

CURAPROX
SWISS PREMIUM ORAL CARE

HYBENX®

Q2/H1 Sales Summary ($)

(CAD 000's)	Q2 2026	Q2 2025	Q1 '26 vs. Q1 '25 (%)	H1 2026	H1 2025	H1 '26 vs. H1 '25 (%)
Pharmaceutical	11,110	9,773	+14%	21,913	20,468	+7%
Oral Health[1]	8,224	-	n/a	11,209	-	n/a
Insecticides	538	406	+32%	658	691	(5%)
Total Company	19,873	10,179	+95%	33,781	21,158	+60%

1. Oral Health Segment acquired March 1, 2026
   - -Q2 2026 was first full quarter of operating results as part of BioSyent
   - -YoY Sales Growth: +9% Q2 '26 vs. Q2 '25
     +9% H1 '26 vs. H1 '25

BioSyent

Q2 Results Comparison

Metric	Q2 2024	Q2 2025 *vs. Q2 2024*	Q2 2026 *vs. Q2 2025*
Revenue (Net Revenues)	$8.94M	$10.18M +14%	$19.87M +95%
EBITDA†	$2.05M	$2.76M +35%	$4.98M +80%
NIAT	$1.58M	$2.02M +28%	$2.85M +41%
Fully Diluted EPS	$0.13	$0.18 +31%	$0.25 +39%
ROE (TTM)	21%	23% +2 pp	24% + 1pp

BioSyent

H1 Results Comparison

Metric	H1 2024	H1 2025 *vs. H1 2024*	H1 2026 *vs. H1 2025*
Revenue (Net Revenues)	$16.68M	$21.16M +27%	$33.78M +60%
EBITDA†	$4.25M	$5.96M +40%	$8.62M +45%
NIAT	$3.35M	$4.34M +30%	$5.19M +20%
Fully Diluted EPS	$0.28	$0.38 +33%	$0.45 +19%

Fully Diluted Earnings per Share (TTM)



Earnings Growth + NCIB Share Buybacks Drive EPS Growth

Acquisition of Oral Science – March 1, 2026

New BioSyent Oral Health Business Unit

- **$25.5M** upfront purchase price (including $6.3M working capital)
  + $1.85M paid for excess working capital
  + performance earn out
  + royalties on future sales of 1 product
- **<6x EBITDA** implied purchase multiple

BioSyent

oral science

Balance Sheet & Income Statement Impact of Acquisition*

Balance Sheet

Provisional Purchase Price Allocation	Amount
Working capital	$8,284,619
Property and equipment	791,813
Intangible assets	19,083,333
Goodwill	3,796,739
Lease liability	(475,357)
Net assets acquired	$31,481,647

Income Statement

$250k/mo. Amortization Expense

Q2 2026: $750k amortization expense on acquired intangible assets

H1 2026: $1M amortization expense on acquired intangible assets

*Subject to change

Going Forward

Pharmaceutical

Oral Health

- Continue growth investment in pharmaceutical + oral health platforms
- Expand ex-Canada revenue on both platforms

YTD 2026 Highlights

- Mar 13, 2026: Paid quarterly dividend of $0.055/share (+10% increase vs. 2025)
- Jun 15, 2026: Paid quarterly dividend of $0.055/share
- Aug 20, 2026: Quarterly dividend of $0.055/share declared
- YTD June 30, 2026: 218,500 shares repurchased and cancelled under NCIB
- Apr 2026: FeraMAX® named #1 recommended iron supplement in Canada for **eleventh** consecutive year
- May 2026: Health Canada approval of Thyconvi®

TAKE A NEW
APPROACH TO
LEVOTHYROXINE
ADMINISTRATION



Thyconvi® is THE FIRST AND ONLY
oral solution of levothyroxine in Canada.

SPEAK WITH YOUR PATIENTS ABOUT TRYING
A TREATMENT THAT GOES DOWN EASIER.

Pr Thyconvi®
(levothyroxine sodium)
oral solution 20 mcg / ml

**Pharmacist will dispense with an oral dosing syringe.*

Thyconvi®
(levothyroxine sodium)
oral solution 20 mcg / ml

THYCONVI - Product Overview

THYCONVI will be the first & only stable oral solution formulation for levothyroxine available in Canada, which provides convenience through flexible accurate dosing of levothyroxine to children & adults

About THYCONVI:

- THYCONVI is an oral solution of levothyroxine (T4)
- For adults and children with difficulty swallowing solid medication
- The solution is free of alcohol/ethanol, sorbitol, sodium benzoate, propylene glycol, sugar, dyes and taste masking.
- Available and patented in the EU (approved 2012) and USA (approval 2020)

THYCONVI Benefits:

- Stable liquid formulation offers consistent & flexible dose accuracy in small dose increments
- Avoids tablet splitting/crushing and dose stacking, a common approach that physicians use to obtain optimum dose - providing individualized dosing
- Avoids potential allergy & intolerance issue with the fillers, binders and dyes in the tablets.

Timelines:

- Health Canada Approved in May 2026
- Full Commercial Launch 2027

- Most recommended iron supplement in Canada - pharmacists and physicians - **11** consecutive years(1)
- Continued innovation and expansion of FeraMAX® product line for iron health

(1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2026 Survey on OTC Counselling and Recommendations

BioSyent

Growth Drivers

Thyconvi® - 2027 launch

Oral health

FeraMAX® Pd Platform – Life Cycle Strategy

Acquisition and in-licensing

Geopolitics, Trade and Economy

- Uncertainty
- Armed conflicts
- Tariffs / Counter-Tariffs
- Inflationary impacts
  - Transportation
  - Supply Chains
  - Cost of Goods
  - Consumer Behaviour

Strong Balance Sheet + Cash Generation
Supports Ongoing Portfolio Opportunities

(CAD 000,000's)	Dec 31, 2025	Mar 1, 2026 (Acquisition Closing Date)	Jun 30, 2026
Cash and GICs	31.9	17.2	12.2
Non-cash Working Capital	4.0	8.2	7.8
Non-current Assets	6.4	29.6	28.6
(Short Term Debt)(1)	-	(8.0)	(2.0)
(Non-current Liabilities)	(0.8)	(0.6)	(0.8)

(1) Short term debt to be fully repaid Sept 30, 2026

Capital Allocation linked to Strategy

First use of capital is to generate revenue/profit growth & portfolio diversification.

Capital-Light, Cash-Generating Business Model



Quarterly Dividends
$8.1 M to Date
Q4’22 – Q3’26

Share Buybacks
$26.5 M to Date
3.4 million shares repurchased since 2018

- 7 new branded product launches in Canada since July 2020
- Capital deployed in acquisitions with ↑ ROIC

  $ 4.2M Tibelia® / Tibella® (tibolone) Acquisition of global rights Sept 2024 <5x EBITDA multiple

  $25.5M Oral Science Acquisition Mar 2026 <6x EBITDA multiple

Stock Information

As at August 18, 2026

Exchange & Trading Symbol	TSXV: RX
Aug 18, 2026 Closing Stock Price (CAD) (TSXV):	**$14.60**
52 Week Hi/Low (TSXV):	**$15.80 / $10.65**
Issued Common Shares:	11,483,849
Treasury – RSU Shares in Trust	(175,014)
Outstanding Common Shares:	11,308,835
Options Outstanding	73,466
RSUs Outstanding	194,789
Fully Diluted Common Shares:	**11,577,090**
P/E Ratio :	**17.13**
EV/EBITDA† (TTM):	**10.75**

BioSyent

BioSyent

WELL CAPITALIZED.

PROFITABLE.

GROWTH ASSETS.

LONG-TERM COMPOUNDING TRACK RECORD.

Reconciliation of EBITDA to NIAT

†EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.

A reconciliation of EBITDA to NIAT for the three and six months ended June 30, 2026 and 2025 is provided in the table below:

	First Quarter (Q2) Ended June 30		First Half (H2) Ended June 30	
	2026	2025	**2026**	2025
EBITDA	**4,976,253**	2,760,149	**8,615,339**	5,961,796
Add: Interest Income	**94,412**	210,934	**261,204**	389,944
Less: Depreciation - Property, Equipment	**(153,869)**	(68,075)	**(247,981)**	(134,982)
Amortization of Intangible Assets	**(895,317)**	(144,566)	**(1,290,166)**	(288,842)
Interest Expense	**(51,371)**	(12,631)	**(82,987)**	(25,734)
Income Tax Expense	**(1,120,671)**	(727,640)	**(2,061,153)**	(1,564,078)
NIAT	**2,849,437**	2,018,171	**5,194,256**	4,338,104